zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 28, 2024 16:32 ET | Zevra Therapeutics
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M ...
Dyadic Logo Current.jpg
Dyadic Reports 2023 Full Year Results and Recent Company Progress
March 28, 2024 16:00 ET | Dyadic International, Inc.
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
ABO-Group Environmen
ABO-Group Environment Annual Results 2023
March 28, 2024 13:56 ET | ABO - Group
Ghent, 28 March 2024 – 18.30 CET – Press release / regulated information 2023 highlights ABO-GROUP saw her revenue grow by 20%, to €85.2 million, thanks to 5 acquisitions and 10% organic...
HEALWELL-AI logo.png
HEALWELL AI Reports Q4 and Full Year 2023 Financial Results
March 28, 2024 07:45 ET | HEALWELL AI Inc.
HEALWELL AI Reports Q4 and Full Year 2023 Financial Results
Persp.jpg
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
March 28, 2024 07:30 ET | Perspective Therapeutics, Inc.
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers...
sequana_rgb_300.png
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
March 28, 2024 03:00 ET | Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION28 March 2024, 08:00 a.m. CET alfapump® – PMA1 submitted to US FDA and accepted for substantive review, extensive feedback just received from...
logo_TRANSGENE.jpg
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
March 27, 2024 12:45 ET | Transgene S.A.
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity...
actelis logo.jpg
Actelis Networks Reports Fiscal Full Year 2023 Results
March 26, 2024 16:30 ET | Actelis Networks, Inc.
FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, hybrid-fiber rapid deployment networking...
Amendment - 2023 Full Year Financial Results
March 26, 2024 09:56 ET | Amaroq Minerals
TORONTO, ONTARIO, March 26, 2024 (GLOBE NEWSWIRE) -- Amendment - 2023 Full Year Financial Results Amendments have been made to the ‘2023 Full Year Financial Results’ announcement released on 26...
2023 Full Year Financial Results
March 26, 2024 03:00 ET | Amaroq Minerals
TORONTO, ONTARIO, March 26, 2024 (GLOBE NEWSWIRE) -- (“Amaroq” or the “Corporation” or the “Company”) 2023 Full Year Financial Results Well-funded and on track to progress development of Nalunaq...